CareMax Management

Management criteria checks 2/4

CareMax's CEO is Carlos de Solo, appointed in May 2011, has a tenure of 13.17 years. total yearly compensation is $3.39M, comprised of 19.2% salary and 80.8% bonuses, including company stock and options. directly owns 5.67% of the company’s shares, worth $506.33K. The average tenure of the management team and the board of directors is 2.3 years and 2.7 years respectively.

Key information

Carlos de Solo

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage	19.2%
CEO tenure	13.2yrs
CEO ownership	5.7%
Management average tenure	2.3yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Jun 20

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

May 13

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Mar 11

CareMax: Numbers Are Strong, Compelling Value On Offer

Sep 16

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

Aug 09

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

Jul 02

CareMax: Network Of Comprehensive Care Centers Serving Medicare Beneficiaries

Oct 18

CEO Compensation Analysis

How has Carlos de Solo's remuneration changed compared to CareMax's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$645m
Dec 31 2023	US$3m	US$650k	-US$683m
Sep 30 2023	n/a	n/a	-US$207m
Jun 30 2023	n/a	n/a	-US$126m
Mar 31 2023	n/a	n/a	-US$103m
Dec 31 2022	US$3m	US$650k	-US$38m
Sep 30 2022	n/a	n/a	-US$52m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$2m	US$419k	-US$7m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	US$12m
Mar 31 2021	n/a	n/a	US$6m
Dec 31 2020	US$3m	US$112k	US$8m
Sep 30 2020	n/a	n/a	US$7m
Dec 31 2019	US$3m	US$48k	US$6m

Compensation vs Market: Carlos's total compensation ($USD3.39M) is above average for companies of similar size in the US market ($USD697.54K).

Compensation vs Earnings: Carlos's compensation has been consistent with company performance over the past year.

CEO

Carlos de Solo (45 yo)

13.2yrs

Tenure

US$3,386,890

Compensation

Mr. Carlos A. de Solo is a Co-Founder of CareMax Medical Group, L.L.C., and serves as President, Chief Executive Officer and Director since May 2011. Mr. de Solo has experience in the healthcare industry....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Carlos de Solo	Co-Founder	13.2yrs	US$3.39m	5.67% $ 506.3k
Kevin Wirges	Executive VP	3.1yrs	US$1.35m	0.15% $ 13.0k
Alberto de Solo	Executive VP & COO	13.2yrs	US$1.82m	2.56% $ 228.9k
Erick Fernandez	Chief Accounting Officer	2.5yrs	no data	no data
Mark Llorente	Chief Administrative Officer & Head of MSO Operations	1.3yrs	no data	no data
Roger Ou	SVP of Finance & Investor Relations	no data	no data	no data
Meredith Longsworth	Senior VP	2.3yrs	no data	no data
Teresa McMeans	Chief Compliance Officer	2.3yrs	no data	no data
Niberto Moreno	Chief Medical Officer & President of Caremax MSO	no data	no data	no data
Nicole Cable	Chief Experience Officer	2.3yrs	no data	no data
Michael Jarjour	Chief Digital Officer	1.5yrs	no data	no data
Paul Rundell	Chief Restructuring Officer	less than a year	no data	no data

2.3yrs

Average Tenure

45yo

Average Age

Experienced Management: CMAX's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Carlos de Solo	Co-Founder	13.2yrs	US$3.39m	5.67% $ 506.3k
Richard Barasch	Advisor to the Board	2.4yrs	US$565.56k	0.066% $ 5.9k
Ralph de la Torre	Director	1.7yrs	US$205.00k	15.85% $ 1.4m
Kevin Berg	Independent Director	1.7yrs	US$216.35k	0.011% $ 949.1
Bryan Cho	Independent Director	3yrs	US$235.00k	0.47% $ 42.3k
Jose Rodriguez	Independent Chairman	3.1yrs	US$322.50k	0.036% $ 3.2k
Vincent Omachonu	Independent Director	3.1yrs	US$205.00k	0.026% $ 2.3k
Ryan O'Quinn	Independent Director	1.7yrs	US$225.00k	0.011% $ 949.1

2.7yrs

Average Tenure

55.5yo

Average Age

Experienced Board: CMAX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

CareMax Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new directors

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

CareMax, Inc. Appoints Ralph De La Torre as Director

High number of new and inexperienced directors

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

CareMax, Inc., Annual General Meeting, Nov 02, 2022

Recent updates

New major risk - Financial position

High number of new directors

CareMax, Inc. announced delayed annual 10-K filing

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

CareMax Announces 1-for-30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

CareMax Receives Non-Compliance Notice From Nasdaq

New major risk - Share price stability

New minor risk - Market cap size

Consensus EPS estimates fall by 64%

Price target increased by 9.1% to US$6.00

Consensus EPS estimates fall by 105%

New minor risk - Profitability

Caremax, Inc. Reports Unaudited Goodwill Impairment for the Three Months Ended September 30, 2023

CareMax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

Consensus EPS estimates fall by 18%, revenue upgraded

Price target decreased by 11% to US$6.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Revenue Guidance for the Full Year of 2023

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Consensus EPS estimates upgraded to US$0.28 loss, revenue downgraded

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

Caremax, Inc. Reaffirms Full Year 2023 Guidance

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$0.42 loss

Consensus EPS estimates upgraded to US$0.49 loss, revenue downgraded

Consensus revenue estimates fall by 12%

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.50

CareMax, Inc. Appoints Ralph De La Torre as Director

Consensus forecasts updated

High number of new and inexperienced directors

CareMax, Inc. (NasdaqGS:CMAX) completed the acquisition of Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Earnings Guidance for the Full Year 2022

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

CareMax, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CareMax, Inc., Annual General Meeting, Nov 02, 2022

CareMax: Numbers Are Strong, Compelling Value On Offer

Price target decreased to US$11.10

Consensus estimates of losses per share improve by 14%

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. Revises Earnings Guidance for the Full Year 2022

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

CareMax, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$11.00

High number of new and inexperienced directors

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

CareMax, Inc. (NasdaqGS:CMAX) entered into an agreement to acquire Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC for approximately $135 million.

Consensus forecasts updated

Price target decreased to US$12.00

Caremax, Inc. Provides Earnings Outlook for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new and inexperienced directors

Consensus estimates of losses per share improve by 40%

Price target decreased to US$13.25

Consensus forecasts updated

Caremax, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: EPS misses analyst expectations

CareMax, Inc. to Report Q4, 2021 Results on Mar 08, 2022

CareMax, Inc. Announces Board Changes

Third quarter 2021 earnings released: US$0.035 loss per share (vs US$0.029 loss in 3Q 2020)

High number of new and inexperienced directors

CareMax: Network Of Comprehensive Care Centers Serving Medicare Beneficiaries

CareMax, Inc. announced delayed 10-Q filing